<DOC>
	<DOCNO>NCT02842372</DOCNO>
	<brief_summary>This non-interventional prospective study investigate treatment response topical application Ectoin Dermatitis Cream 7 % first-line therapy grade I acute skin graft-versus-host disease .</brief_summary>
	<brief_title>Ectoin Dermatitis Cream 7 % First-line Therapy Acute Skin Graft Versus Host Disease</brief_title>
	<detailed_description>Graft-versus-host disease ( GvHD ) medical complication follow receipt transplant tissue genetically different person . In classical sense , acute graft-versus-host-disease characterize selective damage different organ system severity acute GVHD determine assessment degree involvement skin , liver , gastrointestinal tract . In general topical steroid use first line treatment acute grade I skin GvHD accord Dignan et al 2012 . However , administration high dos and/or prolong use topical steroid associate severe side effect , opportunistic infection , significant factor morbidity mortality . Furthermore , result corticosteroid treatment clearly suboptimal , continue complete response rate 20-40 % acute chronic GVHD . Therefore , still remain matter debate whether alternative first line therapy topical steroid overcome problem . Ectoin Dermatitis Cream high quality cream contain 7 % Ectoin without cortisone symptomatic , proactive treatment atopic dermatitis inflammatory skin diseases e.g . radio contact dermatitis . In several clinical study show Ectoin Dermatitis Cream reduce inflammation skin sub-acute period stabilize skin barrier . In acute period , reduces symptoms like itchiness redness skin . In study , Ectoin Dermatitis Cream use therapy grade 1 ( stage 1 2 ) acute skin GvHD patient hypersensitivity corticosteroid show ineffectiveness topical corticosteroid . Following confirmation diagnosis , patient ask investigator whether interested participate current trial . The investigator , take patient consideration free decide receive Ectoin Dermatitis Cream . Patients enrol observational trial treat 14 day Ectoin Dermatitis Cream . Patients respond Ectoin therapy within first 5 7 day treatment , treat topical systemic steroid . However , indication good treatment response , patient treat Ectoin Dermatitis Cream symptom resolve .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Diagnosis acute skin graft versus host disease grade I hypersensitivity corticosteroid ineffectiveness topical corticosteroid Grade IIIV GVHD ( history time study entry ) Use systemic steroid time GVHD Treatment Noncompliance medication Allergic otherwise undesirable reaction Ectoin ingredients topical cream Patients exanthema face Preexisting dermatologic condition ( e.g . eczema , psoriasis , acne etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Acute Graft Versus Host Disease Skin</keyword>
	<keyword>GvHD</keyword>
	<keyword>Ectoin</keyword>
	<keyword>Dermatitis</keyword>
	<keyword>Inflammation skin</keyword>
	<keyword>Topical therapy skin GvHD</keyword>
</DOC>